Categories U.S. Markets News

US new home sales hit 16-month high

Obliterating market estimates, sales of new homes in the United States of America rose to a 16-month high in March, according to official US government data on Tuesday.

According to the report published by the Census Bureau and Department of Housing and Urban Development in the US, sales of single-family homes soared 4.5% to 692,000. The median sale price slipped 9.7% to a two-year low of $302,700.

Representational Image: A Housing Complex in Williamsburg, New York
(Courtesy: Daryan Shamkhali)

The numbers indicate that the Fed holding the borrowing costs back, along with low mortgage rates and a lift in wages have aided the housing market — especially after a disastrous past year.

The number of properties sold where construction is yet to commence is now at 200,000 — this has been the highest since November of 2017, indicating that the market is giving confidence to more buyers.

Among all sales, new home buys are 10% of them. The Midwest region recorded a 176% jump in new home purchases, while the Northeast witnessed a 22.2% drop.

The US data in March is an indicator that the market is returning to its original schedule after being offset by the government shutdown that plagued the end of 2018 and ushered in a tumultuous beginning to 2019.
The March figures mark a return to the original schedule following delays from the government shutdown that ended in January.

 

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top